These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7647423)

  • 1. Screening for prostate cancer. Implications for drug therapy.
    Harwood RH
    Drugs Aging; 1995 May; 6(5):345-50. PubMed ID: 7647423
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular therapy is advancing with drugs that target pathways relevant for several cancers. Foreword.
    Boccon-Gibod L
    BJU Int; 2012 Oct; 110 Suppl 1():1-2. PubMed ID: 23046033
    [No Abstract]   [Full Text] [Related]  

  • 3. Current status and prospects of androgen depletion therapy for prostate cancer.
    Akaza H
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and treatment of patients with prostate cancer: the nurse's role.
    Turner B
    Nurs Stand; 2007 Jun 6-12; 21(39):48-56; quiz 58. PubMed ID: 17569378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine therapy for prostate cancer.
    Labrie F
    Endocrinol Metab Clin North Am; 1991 Dec; 20(4):845-72. PubMed ID: 1778180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Clandestine' prostate cancer haunts.
    Chapman B
    CAP Today; 1996 Feb; 10(2):1, 34-6, 38 passim. PubMed ID: 10160261
    [No Abstract]   [Full Text] [Related]  

  • 7. [5/7 Prostate cancer in the elderly man].
    Mourey L
    Soins Gerontol; 2010; (86):45-6. PubMed ID: 21298971
    [No Abstract]   [Full Text] [Related]  

  • 8. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Haines IE; Gabor Miklos GL
    J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.
    Grosse L; Pâquet S; Caron P; Fazli L; Rennie PS; Bélanger A; Barbier O
    Cancer Res; 2013 Dec; 73(23):6963-71. PubMed ID: 24121496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer and the principles of hormone therapy.
    Drudge-Coates L
    Br J Nurs; 2005 Apr 14-27; 14(7):368-75. PubMed ID: 15924010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncology today: new horizons. Prostate cancer.
    Greifzu SP
    RN; 2000 Jun; 63(6):26-31; quiz 32. PubMed ID: 10897747
    [No Abstract]   [Full Text] [Related]  

  • 12. Screening for osteoporosis in men receiving androgen deprivation therapy.
    Alibhai SM; Yun L; Cheung AM; Paszat L
    JAMA; 2012 Jan; 307(3):255-6. PubMed ID: 22253389
    [No Abstract]   [Full Text] [Related]  

  • 13. Screening and hormonal therapy of localized prostate cancer shows major benefits on survival.
    Labrie F
    Cancer J; 2000 Apr; 6 Suppl 2():S182-7. PubMed ID: 10803834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of prostate cancer].
    Romics I
    Orv Hetil; 2010 Apr; 151(14):580-3. PubMed ID: 20332076
    [No Abstract]   [Full Text] [Related]  

  • 15. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer.
    Voskoboynik M; Staffurth J; Malik Z; Sweeney C; Chowdhury S
    Expert Rev Anticancer Ther; 2014 Nov; 14(11):1253-6. PubMed ID: 25353342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
    Mansueto G; Longo F
    Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169
    [No Abstract]   [Full Text] [Related]  

  • 17. Choice of hormonal therapy for prostate cancer.
    Reese DM
    Lancet; 2000 Apr; 355(9214):1474-5. PubMed ID: 10801162
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prostate antigen as a tumor marker of prostate cancer. (1) Changes of prostate antigen values during anti-androgen therapy].
    Kuriyama M; Takeuchi T; Okano M; Fujimoto Y; Fujihiro S; Nishiura T; Murphy GP; Chu TM
    Nihon Gan Chiryo Gakkai Shi; 1984 Aug; 19(7):1481-7. PubMed ID: 6084037
    [No Abstract]   [Full Text] [Related]  

  • 19. [From the gene to the clinic: prostate cancer death can now be an exception?].
    Labrie F; Cusan L; Gomez JL; Candas B; Bélanger A; Luu-The V; Labrie C; Simard J
    Med Sci (Paris); 2003 Oct; 19(10):910-9. PubMed ID: 14612999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Androgen Deprivation Therapy for Prostate Cancer Increase the Risk of Colorectal Cancer?
    Martling A
    Cancer Control; 2015 Apr; 22(2):261-2. PubMed ID: 26068775
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.